Can a shot keep hepatitis b away after 'Cure'? new trial aims to find out
NCT ID NCT07328711
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard therapy, then check if the virus stays gone for 48 weeks. The goal is to reduce relapse and find better ways to achieve a lasting cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hepatitis B immunoglobulin (HBIG)
What this could lead to
If it works, this could help people with chronic hepatitis B stay virus-free after initial clearance, reducing the chance of relapse and moving closer to a complete cure.
What could go wrong
This is a very early, small study (132 people) with no guarantee of success. HBIG is a temporary boost, not a permanent fix, and may not prevent relapse in the long run.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••